Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

作者：Solange Peters, S.S. Ramalingam, Luis Paz‐Ares, R. Bernabe Caro, Bogdan Żurawski, S.-W. Kim, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Faith E. Nathan, Matthew D. Hellmann · 发表于：Annals of Oncology · 年份：2019 · DOI：10.1093/annonc/mdz394.075 · 被引用次数：33 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies